Study of Pembrolizumab in Locally Advanced Esophageal Adenocarcinoma
Status:
Recruiting
Trial end date:
2025-04-01
Target enrollment:
Participant gender:
Summary
This is a randomized, multicenter phase II study of pembrolizumab in combination with
chemotherapy and chemoradiation in locally advanced esophageal adenocarcinoma to examine the
safety and efficacy of the combination of pembrolizumab with chemotherapy and chemoradiation
in locally advanced esophageal adenocarcinoma as assessed by 1 year disease free survival
rate.